December 5, 2016
G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. a clinical-stage oncology company, announced today a clinical trial collaboration with Genentech, a member of the Roche Group. A Phase 2 clinical trial is expected to begin in the first half of 2017 and will evaluate the combination of Genentech’s immune checkpoint, anti-PD-L1 antibody Tecentriq® (atezolizumab) with G1’s CDK4/6 inhibitor trilaciclib (G1T28) as a first-line treatment for patients with small-cell lung cancer (SCLC) receiving chemotherapy.
October 4, 2016
Medfusion Named Inaugural Member of GE Healthcare Centricity Partner Program
CARY, N.C.– Medfusion, a leading provider of patient experience solutions, today announced that GE Healthcare has named the company as the inaugural member of its Centricity™ Partner Program. GE Healthcare’s Centricity™ Partner Program recognizes Centricity software and services partners and enables them to collaboratively test software and services with GE Healthcare solutions.
September 14, 2016
Tumor Ablation Expert Dr. Fred Lee, Jr. Joins HistoSonics as Board Member, Senior Medical Advisor
Ann Arbor, MI – September 13, 2016 – HistoSonics, Inc. (http://www.histosonics.com ) (the “Company”) announced today that noted radiologist and tumor ablation expert Fred Lee, Jr., MD, has joined the Company as Senior Medical Advisor and Board member to advance HistoSonics’ innovative tissue-destruction technology in liver cancer and other solid tumor applications.
August 23, 2016
Spyryx Biosciences Expands Executive Team, Appoints Pulmonary Industry Leader, Alistair Wheeler, MD, MFPM as Chief Medical Officer
Durham, NC; August 18, 2016 – Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for respiratory diseases, including cystic fibrosis (CF), announced today that Dr. Alistair Wheeler has joined the company in the newly created position of chief medical officer.
July 27, 2016
Clearside Biomedical, Inc. Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
ALPHARETTA, Ga., July 26, 2016 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reports additional top-line data from its Phase 2 clinical trial (TANZANITE).
June 22, 2016
Graybug Vision Expands Executive Team with Appointments of Charles P. Semba, MD, and Ward M. Peterson, PhD
Redwood City, CA – June 21, 2016 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that two prominent industry executives have joined its management team.
June 2, 2016
Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering
ALPHARETTA, Ga., June 01, 2016 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of .00 per share.
May 11, 2016
G1 Therapeutics Secures $47 Million Series C Financing
RESEARCH TRIANGLE PARK, N.C., May 11, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage oncology company, announced today the completion of a $47 million Series C financing led by new investor Cormorant Asset Management. Additional new investors include Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments and Rock Springs Capital.
May 6, 2016
Graybug Vision Announces $44.5 Million Series B Financing
REDWOOD CITY, CA–(Marketwired – May 2, 2016) – Graybug Vision, a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced the closing of a $44.5 million Series B financing.
May 6, 2016
Just Download It: Wyoming Discovers Novel Way to Help Pregnant Mothers
Wyoming is improving its birth outcomes one downloader at a time. An interactive mobile app—Due Date Plus—that the state Medicaid office developed for pregnant women is redefining prenatal education and transforming how Medicaid meets the needs of its pregnant population.